2-oxo-1,3-benzoxathiol-6-yl trifluoromethanesulfonate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: 2-oxo-1,3-benzoxathiol-6-yl trifluoromethanesulfonate
• 英文别名: (2-Oxo-1,3-benzoxathiol-6-yl) trifluoromethanesulfonate；(2-oxo-1,3-benzoxathiol-6-yl) trifluoromethanesulfonate
• 化学式: C₈H₃F₃O₅S₂
• 分子量: 300.236
• InChiKey: UNFFKIKCSMOFAV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  103
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  2-oxo-1,3-benzoxathiol-6-yl trifluoromethanesulfonate 在 水 、 双氧水 、 对甲苯磺酸 、 溶剂黄146 、 sodium hydroxide 作用下， 以 水 、 苯 为溶剂， 反应 186.0h， 生成 2,2-dimethyl-3,3-dioxido-1,3-benzoxathiol-6-yl trifluoromethanesulfonate
  参考文献：
  名称：

  [EN] COMPOUNDS CONTAINING POLYSUBSTITUTED BENZO[D][1,3]OXATHIOLE, BENZO[D][1,3]OXATHIOLE 3-OXIDE OR BENZO[D][1,3]OXATHIOLE 3,3-DIOXIDE AND METHODS/USES THEREOF AS AGONISTS OF G PROTEIN-COUPLED RECEPTOR 119
  [FR] COMPOSÉS CONTENANT DU BENZO[D][1,3]OXATHIOLE, BENZO[D][1,3]OXATHIOLE 3-OXYDE OU DU BENZO[D][1,3]OXATHIOLE 3,3-DIOXYDE POLYSUBSTITUÉ, ET LEURS PROCÉDÉS/UTILISATIONS EN TANT QU'AGONISTES DU RÉCEPTEUR 119 COUPLÉ À LA PROTÉINE G

  摘要：

  提供具有化学式（I）的化合物，其中：X1和X2从O、S、SO和SO2的某些组合中选择；X3从CH、CF和N中选择；X4从CH和N中选择；X6、X6'和X6''从H、卤素以及某些烷基、卤代烷基、烷氧基、羟基烷基和酰胺基中选择；X7和X7'从H、卤素以及某些烷基、卤代烷基、烷氧基、羟基烷基、氨基烷基和酰胺基中选择，或者X7和X7'一起形成环烷基或杂环；A从某些可选择取代的烷氧基、哌嗪基和吡咯烷基中选择。还提供包含这些化合物的组合物，以及与之相关的用途/方法，包括治疗与GPR119失调、2型糖尿病以及相关代谢紊乱相关的疾病和症状。

  公开号：

  WO2019104418A1
• 作为产物：
  描述：

  噻克索酮 、 三氟甲磺酸酐 在 吡啶 作用下， 以86%的产率得到2-oxo-1,3-benzoxathiol-6-yl trifluoromethanesulfonate
  参考文献：
  名称：

  [EN] COMPOUNDS CONTAINING POLYSUBSTITUTED BENZO[D][1,3]OXATHIOLE, BENZO[D][1,3]OXATHIOLE 3-OXIDE OR BENZO[D][1,3]OXATHIOLE 3,3-DIOXIDE AND METHODS/USES THEREOF AS AGONISTS OF G PROTEIN-COUPLED RECEPTOR 119
  [FR] COMPOSÉS CONTENANT DU BENZO[D][1,3]OXATHIOLE, BENZO[D][1,3]OXATHIOLE 3-OXYDE OU DU BENZO[D][1,3]OXATHIOLE 3,3-DIOXYDE POLYSUBSTITUÉ, ET LEURS PROCÉDÉS/UTILISATIONS EN TANT QU'AGONISTES DU RÉCEPTEUR 119 COUPLÉ À LA PROTÉINE G

  摘要：

  提供具有化学式（I）的化合物，其中：X1和X2从O、S、SO和SO2的某些组合中选择；X3从CH、CF和N中选择；X4从CH和N中选择；X6、X6'和X6''从H、卤素以及某些烷基、卤代烷基、烷氧基、羟基烷基和酰胺基中选择；X7和X7'从H、卤素以及某些烷基、卤代烷基、烷氧基、羟基烷基、氨基烷基和酰胺基中选择，或者X7和X7'一起形成环烷基或杂环；A从某些可选择取代的烷氧基、哌嗪基和吡咯烷基中选择。还提供包含这些化合物的组合物，以及与之相关的用途/方法，包括治疗与GPR119失调、2型糖尿病以及相关代谢紊乱相关的疾病和症状。

  公开号：

  WO2019104418A1

文献信息

• Compounds containing polysubstituted benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119
  申请人：PRAMANA PHARMACEUTICALS INC.

  公开号：US11358956B2

  公开（公告）日：2022-06-14

  There are provided compounds having formula (I), in which: X1 and X2 are selected from certain combinations of O, S, SO and SO2; X3 is selected from CH, CF and N; X4 is selected from CH and N; X6, X6′ and X6″ are selected from H, halogen, and certain alkyl, haloalkyl, alkoxy, hydroxyalkyl, and amide groups; X7 and X7′ are selected from H, halogen, and certain alkyl, haloalkyl, alkoxy, hydroxyalkyl, aminoalkyl and amide groups, or both X7 and X7′ together form a cycloalkyl or heterocycle; and A is selected from certain optionally substituted, alkoxy, piperazinyl and pyrrolidinyl groups. Also provided are compositions comprising these compounds, as well as uses/methods related thereto, including treatment of diseases and conditions associated with GPR119 dysregulation, Type 2 diabetes mellitus, and related metabolic disorders. (I)

  提供了具有式(I)的化合物，其中：X1和X2选自O、S、SO和SO2的某些组合；X3选自CH、CF和N；X4选自CH和N；X6、X6′和X6″选自H、卤素和某些烷基、卤代烷基、烷氧基、羟基烷基和酰胺基团；X7和X7′选自H、卤素和某些烷基、卤代烷基、烷氧基、羟基烷基、氨基烷基和酰胺基团，或X7和X7′共同形成环烷基或杂环；A选自某些任选取代的烷氧基、哌嗪基和吡咯烷基团。还提供了包含这些化合物的组合物，以及与之相关的用途/方法，包括治疗与 GPR119 失调、2 型糖尿病和相关代谢紊乱有关的疾病和病症。(I)
• COMPOUNDS CONTAINING POLYSUBSTITUTED BENZO[D][1,3]OXATHIOLE, BENZO[D][1,3]OXATHIOLE 3-OXIDE OR BENZO[D][1,3]OXATHIOLE 3,3-DIOXIDE AND METHODS/USES THEREOF AS AGONISTS OF G PROTEIN-COUPLED RECEPTOR 119
  申请人：PRAMANA PHARMACEUTICALS INC.

  公开号：US20210188825A1

  公开（公告）日：2021-06-24

  There are provided compounds having formula (I), in which: X 1 and X 2 are selected from certain combinations of O, S, SO and SO 2 ; X 3 is selected from CH, CF and N; X 4 is selected from CH and N; X 6 , X 6′ and X 6″ are selected from H, halogen, and certain alkyl, haloalkyl, alkoxy, hydroxyalkyl, and amide groups; X 7 and X 7′ are selected from H, halogen, and certain alkyl, haloalkyl, alkoxy, hydroxyalkyl, aminoalkyl and amide groups, or both X 7 and X 7′ together form a cycloalkyl or heterocycle; and A is selected from certain optionally substituted, alkoxy, piperazinyl and pyrrolidinyl groups. Also provided are compositions comprising these compounds, as well as uses/methods related thereto, including treatment of diseases and conditions associated with GPR119 dysregulation, Type 2 diabetes mellitus, and related metabolic disorders. (I)
• COMPOUNDS CONTAINING BENZO[D][1,3]OXATHIOLE, BENZO[D][1,3]OXATHIOLE 3-OXIDE OR BENZO[D][1,3]OXATHIOLE 3,3-DIOXIDE AND METHODS/USES THEREOF AS AGONISTS OF G PROTEIN-COUPLED RECEPTOR 119
  申请人：PRAMANA PHARMACEUTICALS INC.

  公开号：US20210300907A1

  公开（公告）日：2021-09-30

  There are provided compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide, and benzo[d][1,3]oxathiole 3,3-dioxide, as well as uses/methods related thereto, including treatment of diseases and condition associated with GPR119 dysregulation, Type 2 diabetes mellitus, and related metabolic disorders.
• [EN] COMPOUNDS CONTAINING POLYSUBSTITUTED BENZO[D][1,3]OXATHIOLE, BENZO[D][1,3]OXATHIOLE 3-OXIDE OR BENZO[D][1,3]OXATHIOLE 3,3-DIOXIDE AND METHODS/USES THEREOF AS AGONISTS OF G PROTEIN-COUPLED RECEPTOR 119<br/>[FR] COMPOSÉS CONTENANT DU BENZO[D][1,3]OXATHIOLE, BENZO[D][1,3]OXATHIOLE 3-OXYDE OU DU BENZO[D][1,3]OXATHIOLE 3,3-DIOXYDE POLYSUBSTITUÉ, ET LEURS PROCÉDÉS/UTILISATIONS EN TANT QU'AGONISTES DU RÉCEPTEUR 119 COUPLÉ À LA PROTÉINE G
  申请人：PRAMANA PHARMACEUTICALS INC

  公开号：WO2019104418A1

  公开（公告）日：2019-06-06

  There are provided compounds having formula (I), in which: X1 and X2 are selected from certain combinations of O, S, SO and SO2; X3 is selected from CH, CF and N; X4 is selected from CH and N; X6, X6' and X6'' are selected from H, halogen, and certain alkyl, haloalkyl, alkoxy, hydroxyalkyl, and amide groups; X7 and X7' are selected from H, halogen, and certain alkyl, haloalkyl, alkoxy, hydroxyalkyl, aminoalkyl and amide groups, or both X7 and X7' together form a cycloalkyl or heterocycle; and A is selected from certain optionally substituted, alkoxy, piperazinyl and pyrrolidinyl groups. Also provided are compositions comprising these compounds, as well as uses/methods related thereto, including treatment of diseases and conditions associated with GPR119 dysregulation, Type 2 diabetes mellitus, and related metabolic disorders. (I)

  提供具有化学式（I）的化合物，其中：X1和X2从O、S、SO和SO2的某些组合中选择；X3从CH、CF和N中选择；X4从CH和N中选择；X6、X6'和X6''从H、卤素以及某些烷基、卤代烷基、烷氧基、羟基烷基和酰胺基中选择；X7和X7'从H、卤素以及某些烷基、卤代烷基、烷氧基、羟基烷基、氨基烷基和酰胺基中选择，或者X7和X7'一起形成环烷基或杂环；A从某些可选择取代的烷氧基、哌嗪基和吡咯烷基中选择。还提供包含这些化合物的组合物，以及与之相关的用途/方法，包括治疗与GPR119失调、2型糖尿病以及相关代谢紊乱相关的疾病和症状。